Company news
Zelira Therapeutics Ltd. (ASX:ZLD) news
Every Zelira Therapeutics Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Suspension from Official Quotation - Annual Listing Fees
August 23, 2026
Long Term Suspended Entities
July 10, 2026
Suspension from Quotation
March 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 28, 2026
Transformative US$33M Fundraising into Zeliras HOPE 1 SPV
January 15, 2026
Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund
November 25, 2025
Preliminary Final Report
August 29, 2025
Zelira Therapeutics Secures R&D Loan Facility
July 24, 2025
Publication of ZLT-L-007 IRB Approved Observational Study
May 21, 2025
Zelira secures $1 Million At-the-Market Funding Facility
March 30, 2025
Appendix 4D & FY25 Interim Financial Report
February 26, 2025
Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund
February 18, 2025
Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche
January 27, 2025
September 2024 Quarterly Activities Report
October 29, 2024
Appendix 4C Cash Flow Report
October 29, 2024
Appendix 4E and Financial Report to Shareholders
August 28, 2024
June 2024 Quarterly Activities Report
July 29, 2024
ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting
July 11, 2024
ZLD secures US$1.4M unsecured Chairman loan facility
June 30, 2024
HOPE SPV receives US$681,000 third tranche of funding
May 22, 2024
March 2024 Quarterly Activities Report
April 29, 2024
Zelira receives $919,000 R&D Tax Incentive Scheme Refund
April 15, 2024
Appendix 4D & FY24 Interim Financial Report
February 22, 2024
December 2023 Quarterly Activities Report
January 31, 2024
HOPE SPV receives US$819,000 second tranche of funding
January 7, 2024
September 2023 Quarterly Activities Report
October 30, 2023
Zelira closes $3.25M funding as part of HOPE SPV fundraise
August 16, 2023
June 2023 Quarterly Activities Report
July 31, 2023
Zeliras diabetic nerve pain drug outperforms Lyrica
May 31, 2023
Trading Halt
May 28, 2023
ZLD secures additional US$3.25M investment in HOPE SPV
May 21, 2023
March 2023 Quarterly Activities Report
April 27, 2023
Zelira raises A$1.77 million from US-based investors
March 14, 2023
Appendix 4D & FY23 Interim Financial Report
February 28, 2023
Zelira Executive Director Appointed
February 20, 2023
ZLD secures US$8.6 million funding for HOPE 1 US FDA trials
February 14, 2023
December 2022 Quarterly Activities Report
January 30, 2023
Zelira receives $1.14 million cash R&D Tax Incentive
January 30, 2023
ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
November 20, 2022
September 2022 Quarterly Activities Report
October 30, 2022
ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled
September 14, 2022
Response to ASX Aware Query
August 5, 2022
June 2022 Quarterly Activities Report
July 28, 2022
Zenivol receives formal BfArM approval in Germany
July 12, 2022
Response to ASX Price Query
July 12, 2022
Pause in Trading
July 12, 2022
EDCDM Technology License Agreement Update
June 13, 2022
Zenivol Longitudinal, RWD Trial in Insomnia Results
June 7, 2022
Hope 1 Longitudinal, Real-World Data Trial in ASD Results
May 16, 2022
March 2022 Quarterly Activities Report
April 28, 2022